Keyphrases
Alkylating Agents
6%
Antibody-drug Conjugate
10%
Astrocytic Tumor
10%
Belantamab Mafodotin
10%
Blood-brain Barrier
22%
Brain Tumor
14%
Chemoresistance
10%
Chemotherapy
7%
Chromosome 19
16%
DNA Repair Enzymes
7%
Epidermal Growth Factor Receptor
14%
Erlotinib
8%
ETS1
11%
ETS1 Transcription Factor
10%
Gene Expression
6%
Genetic Modification
8%
Glioblastoma
94%
Glioblastoma Cells
7%
Glioblastoma multiforme
41%
Glioblastoma Xenografts
25%
Glioma
15%
Glioma Cell Lines
11%
Glioma Cells
6%
Histone Acetylation
6%
Immunohistochemical Expression
10%
Intracranial Xenografts
6%
Isocitrate Dehydrogenase 1 (IDH1)
6%
Malignant Glioma
14%
Malignant Potential
12%
Median Survival
7%
Methylation-specific Polymerase Chain Reaction
8%
Methylguanine Methyltransferase
45%
MGMT Promoter Methylation
7%
O6-methylguanine-DNA Methyltransferase
11%
Oligodendroglioma
7%
Orthotopic Glioma
6%
Orthotopic Xenograft
6%
P300
7%
PARP Inhibitor (PARPi)
6%
Patient-derived Xenograft
28%
Promoter Methylation
8%
Radiation Therapy
15%
RBBP4
10%
Targeting Antibodies
10%
Temozolomide
71%
Temozolomide Resistance
24%
Tumor
36%
Urokinase-type Plasminogen Activator
16%
Xenograft
23%
Xenograft Model
10%
Medicine and Dentistry
6 O Methylguanine
5%
Antibody-Drug Conjugate
5%
Apoplexy
5%
Arm
5%
Artery Injury
5%
Autophagy
5%
Biological Marker
8%
Blood Brain Barrier
12%
Carotid Artery Stenosis
5%
Cell Survival
5%
Chromosome 19
5%
Cyclin Dependent Kinase Inhibitor
5%
Depatuxizumab Mafodotin
5%
DNA Methyltransferase
26%
DNA Repair
7%
Enhancer Region
6%
Epidermal Growth Factor Receptor
10%
Epidural Hematoma
5%
Essential Gene
5%
Fluorine-18
5%
Ganglioglioma
19%
Ganglioneuroblastoma
5%
Gene Mutation
6%
Glioblastoma
100%
Hepatocellular Carcinoma
5%
In Vitro
8%
Intracranial Tumor
10%
Isocitrate Dehydrogenase
5%
Lisavanbulin
5%
Methylated DNA Protein Cysteine Methyltransferase
9%
Methylation
10%
Methyltransferase
5%
Molecular Profiling
5%
Neoplasm
33%
P16
5%
PARP Inhibitor
5%
Phenylalanine
5%
Phosphoinositide 3-Kinase
5%
Programmed Cell Death
5%
Promoter Region
12%
Protein MDM2
5%
Radiation Therapy
9%
Sensitization
5%
Short Hairpin RNA
5%
Talirine
5%
Temozolomide
58%
Transcription Factor Ets 1
5%
Urokinase
5%
Veliparib
5%
Xenograft
58%